Brind.

Xilio Therapeutics granted options under Nasdaq Listing Rule 5635(c)(4) on August 2, 2025.

1 report, 1 independent Updated Aug 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Xilio Therapeutics (United States)

Keep exploring

The entities involved

Xilio Therapeutics (United States)
organization
- Xilio Therapeutics shares underperformed the S&P 500 so far this year, based on events of August 14, 2025.09:25

Coverage

Newest first; wire copies grouped

Aug 2GlobeNewswireXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechn